DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types.

Its platform, TwinCell, simulates cell-type-specific behaviour by integrating over 1 billion harmonized single-cell omics data points with causal AI, enabling more precise target identification, drug repositioning and disease understanding.

DeepLife applies this technology across autoimmune, neurodegenerative and cardio metabolic diseases among others. It partners with pharmaceutical and biotech companies on asset de-risking, indication expansion and disease relevant assessment. The company has established strategic collaborations including with Biersdorf in skin disease and aging.

DeepLife leverages cell-type-specific digital twin models to pinpoint the most relevant disease indications for any therapeutic compound. At the core is TwinCell – a large-scale causal model of cell biology that identifies the molecular drivers of disease and how to reverse them. TwinCell combines this insight with large scale single cell multi omics data to build precise models of human cell types and their regulatory networks.

These digital twins replicate real cellular behaviour, predicting preclinical outcomes and enabling researchers to explore disease mechanisms in silico. This approach uncovers how compounds act at the cell-type level, enhancing target validation, biomarker discovery and indication selection.

Applied across the drug development lifecycle, TwinCell accelerates decision making, reduces risk and improves translational relevance. It supports novel target discovery, asset de-risking, indication expansion and pipeline prioritization through strategic collaborations with pharmaceutical and biotech partners.

AgenT is a precision diagnostics company dedicated to transforming the prediction and monitoring of neurodegenerative diseases, with an initial focus on Alzheimer’s disease. Built on more than a decade of research, AgenT has developed a strong scientific and technological foundation combining patented biomarkers, proprietary targeted mass spectrometry methods, and AI-based software. This approach enables the company to generate highly specific, clinically relevant insights from blood samples and to address a major unmet need in brain health: earlier, more scalable, and less invasive detection.

AgenT’s proprietary platform is designed to monitor key biological pathways involved in age-related diseases and to support multiple applications ranging from diagnostics and companion diagnostics to therapeutic target discovery. The company also benefits from a unique proprietary database built from more than 5,000 retrospective plasma samples collected across the US, Europe, and Australia, enriched with longitudinal clinical follow-up data. Through this integrated platform and data strategy, AgenT is positioning itself as a next-generation player in precision medicine for neurodegenerative diseases, with a clear path toward clinical validation, commercial deployment, and strategic partnerships in both healthcare and life sciences.

AgenT’s innovative solutions are built around HORIZON™, a proprietary multiomic platform designed to predict and monitor neurodegenerative diseases through a simple blood sample. HORIZON™ combines patented biomarkers, targeted mass spectrometry, and AI-based software, and can monitor 8 key biological pathways through 85 biomarkers. Its first applications, B-HEALED™ and B-AHEAD™, are blood-based tests designed to predict progression to Alzheimer’s dementia symptoms in cognitively unimpaired and impaired individuals. These products have already shown strong performance in a first multicenter retrospective study involving 632 individuals across the US, Europe, and Australia, with 3x fewer false positives than current tests on the market. AgenT is now advancing these solutions through an ongoing 4,200-participant pivotal clinical validation study.